| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Technical Advances |
From the Departments of Medical Oncology,*
and
Colorectal Surgery,
St. Vincent's Hospital;
School of Pathology,
University of New South
Wales; and Johnson and Johnson Research Pty
Limited,§
Sydney, New South Wales, Australia
The enriched polymerase chain reaction (PCR) assay has been used extensively in the detection of ras gene mutations in many types of human malignancies. Although it is very sensitive, it has a number of features that limit its use in the routine diagnostic laboratory. The aim of this study was to develop a novel enriched PCR strategy, in which the concurrent activity of the restriction enzyme BstNI and Taq polymerase allowed the amplification of mutant K-ras while inhibiting the formation of wild-type product. This restriction endonuclease-mediated selective PCR assay uses three sets of primers, together with BstNI, in the reaction mix, and the amplification products are analyzed by gel electrophoresis. The reliability of the restriction endonuclease-mediated selective PCR assay to detect activated K-ras was determined in a variety of clinical samples, including 139 fresh colorectal carcinomas and 113 paraffin-embedded blocks from 80 separate tumors of the colon and rectum, pancreas, breast, or kidney. Codon 12 mutations of the K-ras oncogene were identified in DNA from both fresh and paraffin-embedded tumors in a rapid, sensitive, and reproducible manner. Mutations were detected in 33 (24%) of the fresh colorectal cancers and 16 (20%) of the paraffin-embedded tumors. These results were 97% concordant in cases in which paraffin blocks and fresh specimens from the same tumor were available for analysis. We conclude that restriction endonuclease-mediated selective PCR is a sensitive, rapid, and robust assay for the detection of point mutations in a variety of clinical samples. Importantly, there is no need for manipulation of the sample once the PCR has been set up, and therefore, the chance of contamination is significantly reduced. In contrast to previous assays, restriction endonuclease-mediated selective PCR is not labor intensive, and its format is suitable for use in routine diagnostic laboratory.
This article has been cited by other articles:
 |
|
 |
|
  G. Amicarelli, E. Shehi, G. M. Makrigiorgos, and D. Adlerstein FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations Nucleic Acids Res., October 11, 2007; (2007) gkm809v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Amicarelli, D. Adlerstein, E. Shehi, F. Wang, and G. M. Makrigiorgos Genotype-Specific Signal Generation Based on Digestion of 3-Way DNA Junctions: Application to KRAS Variation Detection Clin. Chem., October 1, 2006; 52(10): 1855 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, T. Kawasaki, M. Brahmandam, L. Yan, M. Cantor, C. Namgyal, M. Mino-Kenudson, G. Y. Lauwers, M. Loda, and C. S. Fuchs Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing J. Mol. Diagn., August 1, 2005; 7(3): 413 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rao, D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y. Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, et al. Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer J. Clin. Oncol., October 1, 2004; 22(19): 3950 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Lleonart, S. Ramon y Cajal, J. D. Groopman, and M. D. Friesen Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis Nucleic Acids Res., March 22, 2004; 32(5): e53 - e53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhu, W. Qin, H. Ehya, J. Lininger, and E. Sauter Microsatellite Changes in Nipple Aspirate Fluid and Breast Tissue from Women with Breast Carcinoma or Its Precursors Clin. Cancer Res., August 1, 2003; 9(8): 3029 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Ward, A Meagher, I Tomlinson, T O'Connor, M Norrie, R Wu, and N Hawkins Microsatellite instability and the clinicopathological features of sporadic colorectal cancer Gut, June 1, 2001; 48(6): 821 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Bariol, A Field, C R Vickers, and R Ward Regression of gastric T cell lymphoma with eradication of Helicobacter pylori Gut, February 1, 2001; 48(2): 269 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. M. van Houten, M. P. Tabor, M. W. M. van den Brekel, F. Denkers, R. G. A. Wishaupt, J. A. Kummer, G. B. Snow, and R. H. Brakenhoff Molecular Assays for the Diagnosis of Minimal Residual Head-and-Neck Cancer: Methods, Reliability, Pitfalls, and Solutions Clin. Cancer Res., October 1, 2000; 6(10): 3803 - 3816. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. S. Kopreski, F. A. Benko, D. J. Borys, A. Khan, T. J. McGarrity, and C. D. Gocke Somatic Mutation Screening: Identification of Individuals Harboring K-ras Mutations With the Use of Plasma DNA J Natl Cancer Inst, June 7, 2000; 92(11): 918 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Kwok Finding a Needle in a Haystack: Detection and Quantification of Rare Mutant Alleles Are Coming of Age Clin. Chem., May 1, 2000; 46(5): 593 - 594. [Full Text] [PDF]
|
|
|
|
|
|
A. V. Todd, C. J. Fuery, H. L. Impey, T. L. Applegate, and M. A. Haughton DzyNA-PCR: Use of DNAzymes to Detect and Quantify Nucleic Acid Sequences in a Real-Time Fluorescent Format Clin. Chem., May 1, 2000; 46(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. WARD, C. SHEEHAN, M. NORRIE, T. APPLEGATE, C. FUERY, H. IMPEY, N. HAWKINS, and A. TODD Factors Influencing the Detection of Mutant K-ras in the Serum of Patients with Colorectal Cancer Ann. N.Y. Acad. Sci., April 1, 2000; 906(1): 17 - 18. [Full Text] [PDF]
|
|
|
|
|
|
C. D. GOCKE, F. A. BENKO, M. S. KOPRESKI, and D. B. EVANS Enrichment Methods for Mutation Detection Ann. N.Y. Acad. Sci., April 1, 2000; 906(1): 31 - 38. [Full Text] [PDF]
|
|
|
|
|
|
J. Zujewski, I. D. Horak, C. J. Bol, R. Woestenborghs, C. Bowden, D. W. End, V. K. Piotrovsky, J. Chiao, R. T. Belly, A. Todd, et al. Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer J. Clin. Oncol., February 14, 2000; 18(4): 927 - 927. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
